Additionally, treatment of FG cells with different concentrations (0–200 μM) of OICR-9429 compound resulted in increased cell death in non-CSCs in a dose-dependent manner (Fig. 5f), suggesting that KMT2A may serve as a potential therapeutic target for both subpopulations of PC cells, especially since gene expression data derived from TCGA clinical datasets show a significant increase in KMT2A expression levels in PDAC patients as compared to the normal pancreas (Fig. 5g). This evidence concerns the gene KMT2A and pachyonychia congenita.